InnoCan Pharma Corporation
INNO
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.40M | 8.62M | 8.64M | 6.77M | 4.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.40M | 8.62M | 8.64M | 6.77M | 4.89M |
| Cost of Revenue | 992.00K | 845.00K | 646.00K | 767.00K | 604.00K |
| Gross Profit | 4.41M | 7.78M | 8.00M | 6.00M | 4.29M |
| SG&A Expenses | 5.01M | 7.05M | 7.04M | 6.79M | 4.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.32M | 8.27M | 8.11M | 7.98M | 5.79M |
| Operating Income | -919.00K | 352.00K | 532.00K | -1.21M | -894.00K |
| Income Before Tax | 3.00K | 702.00K | 1.43M | -1.22M | -582.00K |
| Income Tax Expenses | 51.00K | 418.00K | 478.00K | 234.00K | 214.00K |
| Earnings from Continuing Operations | -48.00K | 284.00K | 956.00K | -1.45M | -796.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -66.00K | -574.00K | -619.00K | -313.00K | -87.00K |
| Net Income | -114.00K | -290.00K | 337.00K | -1.77M | -883.00K |
| EBIT | -919.00K | 352.00K | 532.00K | -1.21M | -894.00K |
| EBITDA | -913.00K | 361.00K | 542.00K | -1.20M | -886.00K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 287.01M | 281.64M | 280.66M | 269.82M | 267.07M |
| Average Diluted Shares Outstanding | 287.01M | 281.64M | 280.66M | 269.82M | 267.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |